Sugemalimab (2) – Cejemly®

Name: Frühe Nutzenbewertungen nach § 35a SGB V
Creator: Gemeinsamer Bundesausschuss

Stage III non-small cell lung cancer, EGFR-, ALK- and ROS1-negative, PD-L1 ≥ 1 per cent, which has not progressed following platinum-based chemoradiotherapy

active procedures repealed resolutions


01.10.2026	01.04.2027	Sugemalimab (2)	Cejemly®	Gentili Pharma GmbH	Oncological diseases	Stage III non-small cell lung cancer, EGFR-, ALK- and ROS1-negative, PD-L1 ≥ 1 per cent, which has not progressed following platinum-based chemoradiotherapy	n.d.	active procedure
01.10.2026	01.04.2027	Sugemalimab (1)	Cejemly®	Gentili Pharma GmbH	Oncological diseases	Non-small cell lung cancer, first-line treatment, in combination with platinum-based chemotherapy	n.d.	active procedure

<< List of all resolutions